Kenneth C. Griffin was student at the Harvard University, graduating with a degree in 1989. He founded the Hedge fund Citadel and serves as its Chairman today. His net worth is around $20.8 billion dollars.
Ken Griffin’s portfolio includes a diversified set of large-cap and infrastructure-linked stocks, reflecting a long-term investment approach focused on liquidity and market leadership. Key investment holdings in Griffin’s portfolio (top five stocks directly) include:
1. iShares Core S&P 500 ETF (BlackRock Institutional Trust Company N.A.) — Broad-market exposure via a highly liquid S&P 500 index investment, aligning with a core, diversified portfolio strategy using exchange-traded stocks.
2. Sunbelt Rentals Holdings Inc — A play on construction and industrial demand trends, positioning the investment portfolio in fleet rental and equipment supply dynamics that tend to benefit from infrastructure and business activity.
3. Amazon.com Inc. — Strong conviction in large-scale e-commerce, cloud (AWS), and digital advertising, emphasizing growth and durable competitive advantages within major market stocks.
4. NVIDIA Corp — High-growth exposure to AI compute and accelerated computing platforms, consistent with Griffin’s investment focus on technology leaders driving major industry shifts.
5. Apple Inc — Concentrated exposure to premium consumer technology and a powerful ecosystem, highlighting stability and cash-generation characteristics in leading blue-chip stocks.
Overall, Ken Griffin’s investment portfolio approach balances broad index participation with concentrated stock investments across technology, cloud, AI infrastructure, and industrial/maintenance services—positioning for both resilience and growth within U.S. market leaders.
Obesity drugs like Mounjaro and Zepbound could help the drugmaker power ahead for years. Its Alzheimer's drug Kisunla and broad pipeline add another layer of long-term potential.
His purchases increased his exposure to pharmaceuticals, medical devices, diagnostics, and diabetes care. AbbVie is relying on drugs like Skyrizi and Rinvoq to replace Humira's ...
Griffin's Citadel hedge fund nearly quadrupled its stake in Eli Lilly in Q2. Lilly's diabetes and obesity drugs continue to enjoy impressive momentum.
Analyze Ken Griffin's top 5 holdings in August 2026, featuring Micron Technology (MU) and insights into the Citadel CEO's latest investment strategy.
Explore the 5 highest dividend-yielding stocks in Ken Griffin's Citadel portfolio for July 2026, including top income holdings like Elme Communities (WRE).
Kenneth Cordele Griffin is an American hedge fund manager, CEO and investor. He is the founder of Citadel LLC and Citadel Securities, and has an estimated net worth of $27.2 billion.
Citadel LLC is a multinational hedge fund founded by Kenneth Cordele Griffin.
Kenneth Cordele Griffin's net worth is estimated to be $27.2 billion.
Griffin has donated $1.56 billion to various charitable causes, primarily in the fields of education, economic mobility and medical research. He has also contributed to political candidates and causes, mainly of the Republican Party.